Hansa Biopharma Announces Late-Breaking Abstract Selection for ASN Kidney Week

Hansa Biopharma has announced that a late-breaking abstract from its PAES study will be presented orally at the ASN Kidney Week during the High-Impact Clinical Trials session. This presentation will focus on the clinical relevance of its Idefirix (imlifidase) therapy for kidney transplantation and antibody-mediated rejection, providing new data on the study's outcomes.